“Basilea Pharmaceutica AG – Product Pipeline Review – 2015
Summary
Global Markets Direct’s, ‘Basilea Pharmaceutica AG – Product Pipeline Review – 2015’, provides an overview of the Basilea Pharmaceutica AG’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Basilea Pharmaceutica AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides brief overview of Basilea Pharmaceutica AG including business description, key information and facts, and its locations and subsidiaries
– The report reviews current pipeline of Basilea Pharmaceutica AG’s human therapeutic division and enlists all their major and minor projects
– The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
– Special feature on out-licensed and partnered product portfolio
– The report summarizes all the dormant and discontinued pipeline projects
– Latest company statement
– Latest news and deals relating to the Basilea Pharmaceutica AG’s pipeline products
Reasons to buy
– Evaluate Basilea Pharmaceutica AG’s strategic position with total access to detailed information on its product pipeline
– Assess the growth potential of Basilea Pharmaceutica AG in its therapy areas of focus
– Identify new drug targets and therapeutic classes in the Basilea Pharmaceutica AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
– Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
– Develop strategic initiatives by understanding the focus areas of Basilea Pharmaceutica AG and exploit collaboration and partnership opportunities
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Plan mergers and acquisitions effectively by identifying the most promising pipeline of Basilea Pharmaceutica AG
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Explore the dormant and discontinued projects of Basilea Pharmaceutica AG and identify potential opportunities in those areas
– Avoid Intellectual Property Rights related issues”
“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Basilea Pharmaceutica AG Snapshot 5
Basilea Pharmaceutica AG Overview 5
Key Information 5
Key Facts 5
Basilea Pharmaceutica AG – Research and Development Overview 6
Key Therapeutic Areas 6
Basilea Pharmaceutica AG – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Basilea Pharmaceutica AG – Pipeline Products Glance 13
Basilea Pharmaceutica AG – Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Basilea Pharmaceutica AG – Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Basilea Pharmaceutica AG – Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Basilea Pharmaceutica AG – Drug Profiles 19
isavuconazonium sulfate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ceftobiprole medocaril 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
BAL-101553 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BAL-30072 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BAL-3833 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CCT-196969 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CCT-241161 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule for Inflammatory Diseases 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules for Hematological and Solid Cancers 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit Beta-Lactamase for Bacterial Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Basilea Pharmaceutica AG – Pipeline Analysis 33
Basilea Pharmaceutica AG – Pipeline Products by Target 33
Basilea Pharmaceutica AG – Pipeline Products by Route of Administration 35
Basilea Pharmaceutica AG – Pipeline Products by Molecule Type 36
Basilea Pharmaceutica AG – Pipeline Products by Mechanism of Action 37
Basilea Pharmaceutica AG – Recent Pipeline Updates 38
Basilea Pharmaceutica AG – Dormant Projects 49
Basilea Pharmaceutica AG – Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
BAL-2299 50
Basilea Pharmaceutica AG – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54″
“List of Tables
Basilea Pharmaceutica AG, Key Information 5
Basilea Pharmaceutica AG, Key Facts 5
Basilea Pharmaceutica AG – Pipeline by Indication, 2015 7
Basilea Pharmaceutica AG – Pipeline by Stage of Development, 2015 9
Basilea Pharmaceutica AG – Monotherapy Products in Pipeline, 2015 10
Basilea Pharmaceutica AG – Out-Licensed Products in Pipeline, 2015 11
Basilea Pharmaceutica AG – Out-Licensed Products/ Combination Treatment Modalities, 2015 12
Basilea Pharmaceutica AG – Pre-Registration, 2015 13
Basilea Pharmaceutica AG – Filing rejected/Withdrawn, 2015 14
Basilea Pharmaceutica AG – Phase II, 2015 15
Basilea Pharmaceutica AG – Phase I, 2015 16
Basilea Pharmaceutica AG – Preclinical, 2015 17
Basilea Pharmaceutica AG – Discovery, 2015 18
Basilea Pharmaceutica AG – Pipeline by Target, 2015 33
Basilea Pharmaceutica AG – Pipeline by Route of Administration, 2015 35
Basilea Pharmaceutica AG – Pipeline by Molecule Type, 2015 36
Basilea Pharmaceutica AG – Pipeline Products by Mechanism of Action, 2015 37
Basilea Pharmaceutica AG – Recent Pipeline Updates, 2015 38
Basilea Pharmaceutica AG – Dormant Developmental Projects,2015 49
Basilea Pharmaceutica AG – Discontinued Pipeline Products, 2015 50
Basilea Pharmaceutica AG, Subsidiaries 51″
“List of Figures
Basilea Pharmaceutica AG – Pipeline by Top 10 Indication, 2015 7
Basilea Pharmaceutica AG – Pipeline by Stage of Development, 2015 9
Basilea Pharmaceutica AG – Monotherapy Products in Pipeline, 2015 10
Basilea Pharmaceutica AG – Out-Licensed Products in Pipeline, 2015 11
Basilea Pharmaceutica AG – Pipeline by Top 10 Target, 2015 33
Basilea Pharmaceutica AG – Pipeline by Top 10 Route of Administration, 2015 35
Basilea Pharmaceutica AG – Pipeline by Top 10 Molecule Type, 2015 36
Basilea Pharmaceutica AG – Pipeline Products by Top 10 Mechanism of Action, 2015 37″
